In the last decade, the IL-23/IL-17 pathway has been highlighted as an essential driver of psoriasis; treatment regimens therapeutically inhibiting this pathway by IL-23- or IL-17-blocking antibodies have proven highly effective in clinical use [2–4]. Here, IL17A is linked to psoriasis.